Among the many drugs targeting some of the PPAR, the pan-PPAR agonist lanifibranor, an indole sulfonamide derivative, has attracted much attention, since on top of our studies demonstrating marked effects in experimental cirrhosis [94]. The gene discussed is PPARA; the disease is Cirrhosis.